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Introduction: Mesenchymal stromal cells (MSCs) have been extensively studied for their promising capabilities in
regenerative medicine. Although bone marrow is the best-known source for isolating equine MSCs, non-invasive
alternative sources such as umbilical cord blood (UCB), umbilical cord matrix (UCM), and peripheral blood (PB) have
also been reported.
Methods: Equine MSCs from three non-invasive alternative sources were isolated from six individual mares (PB) and
their foals (UCB and UCM) at parturition. To minimize inter-horse variability, the samples from the three sources
were matched within the same mare and for UCB and UCM even within the same foal from that specific mare. The
following parameters were analyzed: (i) success rate of isolation, (ii) proliferation capacity, (iii) tri-lineage
differentiation ability, (iv) immunophenotypical protein, and (v) immunomodulatory mRNA profiles. Linear regression
models were fit to determine the association between the source of MSCs (UCB, UCM, PB) and (i) the moment of
first observation, (ii) the moment of first passage, (iii) cell proliferation data, (iv) the expression of markers related to
cell immunogenicity, and (v) the mRNA profile of immunomodulatory factors, except for hepatocyte growth factor
(HGF) as no normal distribution could be obtained for the latter variable. To evaluate the association between the
source of MSCs and the mRNA expression of HGF, the non-parametric Kruskal-Wallis test was performed instead.
Results: While equine MSCs could be isolated from all the UCB and PB samples, isolation from UCM was successful
in only two samples because of contamination issues. Proliferation data showed that equine MSCs from all three
sources could be easily expanded, although UCB-derived MSCs appeared significantly faster in culture than PB- or
UCM-derived MSCs. Equine MSCs from both UCB and PB could be differentiated toward the osteo-, chondro-, and
adipogenic lineage, in contrast to UCM-derived MSCs in which only chondro- and adipogenic differentiation could
be confirmed. Regardless of the source, equine MSCs expressed the immunomodulatory genes CD40, CD80, HGF,
and transforming growth factor-beta (TGFβ). In contrast, no mRNA expression was found for CD86, indoleamine
2,3-dioxygenase (IDO), and tumor necrosis factor-alpha (TNFα).
Conclusions: Whereas UCM seems less feasible because of the high contamination risks and low isolation success
rates, UCB seems a promising alternative MSC source, especially when considering allogeneic MSC use.* Correspondence: catharina.deschauwer@ugent.be
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In the past decade, mesenchymal stromal cells (MSCs)
from humans as well as a variety of other animal species
have received tremendous attention because of their po-
tential for cell-based therapies based on their immuno-
modulatory and anti-inflammatory capacities. The low
immunogenicity of MSCs, indicated by the absence of the
expression of major histocompatibility complex (MHC)
class II and co-stimulatory molecules CD40, CD80, and
CD86, enables their use in clinical allogeneic applications
[1]. Moreover, numerous soluble factors play an essential
role in the regulation of MSC-mediated immunosuppres-
sion by inhibiting T-cell proliferation [2,3]. It has been
suggested that the release of these secreted factors like
hepatocyte growth factor (HGF) and transforming growth
factor-beta (TGF-β) and the induction of indoleamine
2,3-dioxygenase (IDO) mediate the immunosuppressive
effects of MSCs [4,5]. Moreover, tumor necrosis factor-
alpha (TNFα) and interferon-gamma (IFNγ) stimulate
the secretion of immunomodulatory mediators from
MSCs [3,6].
In general, most cell-based therapies consist of the use
of autologous MSCs. Nevertheless, given their immuno-
suppressive capacities, MSCs seem perfectly suited for
cellular therapy in allogeneic settings [4]. An allogeneic
source would provide an off-the-shelf, more standardized,
and readily available product without the inherent lag
period associated with isolation and expansion of autolo-
gous MSCs [7,8]. Some preliminary studies have suggested
that equine allogeneic MSCs can be used without eliciting
an apparent cell-mediated immune response in horses.
Indeed, a study by Guest and colleagues [9] found that
the injection of allogeneic bone marrow (BM)-derived
MSCs did not cause any observable cell-mediated immune
response from the host. In a later study by Carrade and
colleagues [10], no significant differences could be demon-
strated either in the type or in the degree of inflammation
when using autologous or related or unrelated allogeneic
cells. These findings indicate that allogeneic MSCs may be
both a safe and practical alternative treatment option for
equine orthopedic injuries.
Traditionally, BM and adipose tissue have been used
to harvest equine MSCs. Issues concerning the ease of
isolation, expansion characteristics, and donor site com-
plications warrant the search for alternative sources [11].
The MSCs from umbilical cord blood (UCB) and umbilical
cord matrix (UCM) can be easily collected at parturition
without harming the mare or the foal, expanded and sub-
sequently cryopreserved, and as such be readily available
at the time of injury [8]. Thus, by using these non-invasive
sources, the optimal time for treatment can be determined
by the clinician in sharp contrast to the use of MSCs from
BM or adipose tissue, for which the time for cellular ex-
pansion must be taken into account [12]. Nevertheless,cryopreservation of MSCs implies a long-term, expensive
storage [12]. Peripheral blood (PB) is also considered an
attractive alternative since the collection of a venous blood
sample is a minimally invasive and easy procedure that
can be performed at any time [13,14].
Therefore, the aim of the present study was to analyze
and compare these three attractive sources of equine
MSCs (that is, UCB, UCM, and PB). To this end, MSCs
were characterized both functionally as well as immu-
nophenotypically by analyzing the following parameters:
(i) success rate of isolation, (ii) proliferation capacity,
(iii) tri-lineage differentiation ability, (iv) immunophenoty-
pical protein profile, and (v) immunomodulatory mRNA
profile.
Materials and methods
Media
The culture medium for UCB and PB cultures contained
low-glucose Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen Corporation, Carlsbad, CA, USA), 30% fetal
calf serum (FCS) (Gibco-BRL, now part of Invitrogen,
Ghent, Belgium), 10−7 M low dexamethazone, 50 μg/mL
gentamycine, 10 μL/mL antibiotic antimycotic solution
(consisting of 10,000 units penicillin, 10 mg streptomycin,
and 25 μg amphotericin B per mL), 250 ng/mL fungizone
(all from Sigma-Aldrich, Bornem, Belgium) and 2 mM
ultraglutamine (Invitrogen, Ghent, Belgium), based on
the medium described by Koch and colleagues [15]. The
expansion medium was identical to the culture medium
but without dexamethasone. The UCM culture medium
contained low-glucose DMEM, 15% FCS, 50 μg/mL
gentamycine, 10 μL/mL antibiotic antimycotic solution,
and 250 ng/mL fungizone. Osteogenic medium consisted
of low-glucose DMEM, 10% FCS, 0.2 mM L-ascorbic acid-
2-phosphate (Fluka: part of Sigma-Aldrich), 100 nM
dexamethasone, 10 mM β-glycerophosphate, 50 μg/mL
gentamycine, and 10 μL/mL antibiotic antimycotic solution.
Chondrogenic medium was based on the basal differenti-
ation medium from Lonza, Basel, Switzerland, complemen-
ted with 10 ng/mL TGF-β3 (Sigma-Aldrich). Adipogenic
induction medium contained low-glucose DMEM, 1 μM
dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine,
10 μg/mL rh-insuline, 0.2 mM indomethacin, 15% rabbit
serum (all from Sigma-Aldrich), 50 μg/mL gentamycine,
and 10 μl/mL antibiotic antimycotic solution. The adipo-
genic maintenance medium was identical to the adipogenic
induction medium but without dexamethasone, indometh-
acin, and 3-isobutyl-1-methylxanthine.
Collection of umbilical cord blood, umbilical cord matrix,
and peripheral blood
UCB was collected from warmblood full-term born foals
immediately after birth. After clamping and disinfecting
of the umbilical cord with 70% alcohol, the umbilical
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was drained by gravity into a standard blood donor bag
(Terumo, Heverlee, Belgium®; Terumo BCT, Lakewood,
CO, USA) and subsequently stored at 4°C. Samples were
processed only if (i) at least 150 mL UCB was collected,
(ii) storage time was less than 15 hours, and (iii) no
signs of coagulation or hemolysis were present [16].
Once the umbilical cord was ruptured spontaneously, a
clamp was placed on each end of the amniotic part,
after which the umbilical cord was rinsed with tap water
and iodine soap to remove the gross contamination [17]
and disinfected with 70% alcohol. Subsequently, a 5-cm-
long piece was obtained from the middle of the disin-
fected umbilical cord with a sterile scalpel blade and
stored in phosphate-buffered saline containing 50 μg/
mL gentamicin at 4°C. At the same moment, PB from
the vena jugularis of the mares (ages between 4 and 16
years) was collected into two vacuum blood tubes con-
taining heparin as anti-coagulant and stored at 4°C until
further processing. The study was approved by the Eth-
ical Committee of the Faculty of Veterinary Medicine of
Ghent University (EC2010/147).
Isolation and culture of equine mesenchymal
stromal cells
Equine MSCs derived from UCB and PB were isolated
and cultured as previously described [18]. Briefly, UCB
or PB was centrifuged at 1,000 g for 20 minutes at room
temperature (RT). After diluting of the obtained buffy
coat fraction 1:1 (vol:vol) with Hanks’ balanced salt solu-
tion (HBSS), the cell suspension was gently layered on
an equal volume of Percoll® (density 1.080 g/mL; GE
Healthcare, Little Chalfont, Buckinghamshire, UK) and
centrifuged for 15 minutes at 600 g at RT. The interphase,
containing the mononuclear cell (MNC) fraction, was col-
lected and washed three times with HBSS by centrifuging
10 minutes at 200 g at RT. Cell viability and concentration
were determined by trypan blue exclusion by using the
improved Neubauer hemocytometer. The MNCs were
seeded in culture medium at 1 × 106 cells/mL in un-
coated T-25 culture flasks using 12-mL culture medium
and incubated at 37.5°C in a humidified atmosphere
containing 5% CO2. Non-adherent cells were removed
the following day by completely replacing the culture
medium, after which the medium was exchanged twice
a week. When numerous colonies of adherent cells were
observed, cells were detached by using 0.083% trypsin-
ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich,
Bornem, Belgium) and further passaged in expansion
medium, irrespectively of their source.
Equine MSCs derived from UCM were also isolated and
cultured as previously described [19]. Briefly, the umbilical
cord was disinfected with Octeniderm® antiseptic spray
(Schülke & Mayr, Norderstedt, Germany) in a laminarflow hood, after which the umbilical arteries and vein were
removed. The UCM was minced finely (0.5 cm2) by using
sterile scissors in a sterile glass Petri dish containing UCM
culture medium. Subsequently, the explants were trans-
ferred to a T-25 culture flask in 6 mL UCM culture
medium and incubated at 37.5°C in a humidified atmos-
phere containing 5% CO2. The explants were left undis-
turbed for 3 days, after which the medium was exchanged.
Ten days after the start of the culture, the explants were
removed and culture medium was exchanged again. Cells
were detached with 0.083% trypsin-EDTA when numerous
colonies of adherent cells were observed and further
passaged in expansion medium.Proliferation studies
MSCs isolated from UCB, UCM, or PB were followed
during five subsequent passages and for each passage,
cell concentration was determined in order to calculate
the cell doubling number (CDN) and the population
doubling time (PDT) by using following formula: CDN =
ln (Nf/Ni)/ln 2, where Nf is the final number of cells and
Ni the initial number of cells, and PDT= cell culture time
(in days)/CDN.Tri-lineage differentiation
After two passages, approximately 1 × 106 undifferentiated
MSCs were used to perform the tri-lineage differentiation
experiments, exactly as previously described [14,18].
Non-induced cells in expansion medium were used as
negative controls. Osteogenic differentiation was per-
formed in six-well culture dishes with approximately
3,000 undifferentiated MSCs/cm2 which were cultured
in expansion medium until 90% to 100% confluency was
reached. Subsequently, osteogenic differentiation was
induced with osteogenic medium that was exchanged
twice a week, and evaluated after 20 days of culture by
using the Alizarin Red S histological staining as well as
by detecting alkaline phosphatase activity (Millipore,
Overijse, Belgium). Chondrogenic differentiation was
performed by using a micromass culture system; that is,
2.5 × 106 cells were centrifuged in 15-mL Falcon tubes
at 150 g for 5 minutes at RT, after which the chondro-
genic medium was added without disturbing the cell pel-
let. The medium was exchanged every 3 or 4 days during
3 weeks, after which the chondrogenic differentiation was
evaluated by the Alcian blue histological staining. To initi-
ate the adipogenic differentiation, 2.1 × 104 undifferenti-
ated MSC/cm2 were seeded in six-well culture dishes and
cultured until 100% confluency. Subsequently, cells were
exposed to four cycles of 72-hour culturing in the adipo-
genic induction medium and 24 hours of culturing in the
adipogenic maintenance medium, followed by five consecu-
tive days of culturing in adipogenic maintenance medium.
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cellular accumulation of lipid droplets.Immunophenotypical protein profile as determined by
multi-color flow cytometry
Following the criteria of the International Society for
Cellular Therapy, human MSCs need to express CD29,
CD44, CD73, CD90, and CD105 and lack expression of
CD14, CD34, CD45, CD79α, and MHC-II [20]. Undiffer-
entiated equine MSCs from the third/fourth passage were
immunophenotyped by using multicolor flow cytometry,
exactly as previously described [21]. A detailed description
of monoclonal antibody (mAb) clones and dilutions is
given in Table 1. Commercially available mAbs were
validated for recognizing equine epitopes by using
freshly isolated equine MNCs, lymphocytes, or primary
endothelial cells as appropriate positive control cells
(Table 1) [21]. The following combinations of marker panels
were assessed: CD29-Alexa488/MHC II-RPE/CD44-APC/
7-AAD (subset 1), CD105-RPE/CD90-Alexa647/7-AAD
(subset 2), CD45-Alexa488/CD73-RPE/7-AAD (subset 3),
and the monocyte marker-Alexa488/CD79α-Alexa647
(subset 4). To identify the viable cells, 7-AAD was used
in the first three subsets. The presence of MHC-I on theTable 1 Overview of the marker panels of primary monoclona
equine MSC
Subset Marker Compan
Multicolor FCM 1 CD29-Alexa488+ Biolegend
MHC-II− Serotec
7-AAD− Calbioche
CD44-APC+ BD
2 CD105-RPE+ Serotec
7-AAD− Calbioche
CD90+ VMRD
3 CD45-Alexa488− Serotec
CD73+ Abcam
7-AAD− Calbioche
4 Monocyte-Alexa488− Serotec
CD79α-Alexa647− Serotec
Single-color FCM MHC-I+ VMRD
Secondary Ab 1 and 3 Sheep anti-mouse IgG-RPE Sigma-Al
2 Goat anti-mouse IgG-Alexa647 Invitroge
Isotype controls 1 and 4 Mouse IgG1-Alexa488 Biolegend
1-3 Mouse IgG1-RPE Biolegend
1 Rat IgG2b-APC Biolegend
2 Mouse IgM BD
3 Mouse IgG2-Alexa488 Biolegend
4 Mouse IgG1-Alexa647 Biolegend
7-AAD, 7-aminoactinomycin D; FCM, fluorescence correlation microscopy; MHC, ma
secondary antibody.cell surface of the undifferentiated MSCs was analyzed
separately as this mAb could not be included in any of
the subsets.Immunomodulatory mRNA profile as determined by
quantitative polymerase chain reaction
For each source, 1 × 106 MSCs from the fourth passage
were stored in freezing medium, consisting of high-
glucose DMEM, 10% FCS, and 20% dimethylsulphoxide
(DMSO) (Sigma-Aldrich), at −80°C until RNA extraction.
Total RNA was isolated with the RNeasy Mini Kit (Qiagen,
Hilden, Germany) in accordance with the instructions
of the manufacturer, including an on-column DNAse
treatment for 30 minutes with RNase free DNAse (Qiagen).
After a minus RT control to check for contaminating
genomic DNA, 100 ng of RNA was reverse-transcribed
into cDNA by using the Iscript advanced cDNA synthesis
kit (Bio-Rad, Nazareth-Eke, Belgium).
In a preliminary experiment, the expression stability of
eight commonly used reference genes [22,23] was deter-
mined in the MSC samples by using geNorm software
[24] (Table 2). Applying this software program indicated
beta actin (ACTB), succinate dehydrogenase complex,
subunit A (SDHA), ribosomal protein L32 (RPL32), andl antibodies and 7-AAD to immunophenotype
y Clone Sec Ab Dilution Positive control
TS2/16 1:20 MNCs
CVS20 RPE 1:50 MNCs
m
IM7 1:20 MNCs
SN6 1:10 Endothelial cells
m
DH24A Alexa647 1:100 MNCs
F10-89-4 1:5 MNCs
10f1 RPE 1:5 Lymphocytes
m
MAC387 1:2.5 MNCs
HM57 1:2.5 MNCs
PT85A RPE 1:66 MNCs
drich 1:20
n Corporation 1:200
1:20
1:10
1:20
Alexa647 1:50
1:20
1:100
jor histocompatibility complex; MNC, mononuclear cell; Sec Ab,
Table 2 Primer sequences used for the real-time polymerase chain reaction studies
Gene Name Primer sequence 5′→ 3′ Amplicon
size, bp
Ta, °C Efficiency, % Correlation
Reference
genes
ACTB Beta actin CCAGCACGATGAAGATCAAG 88 60 98 0.998
GTGGACAATGAGGCCAGAAT
GAPDH Glyceraldehyde-3-phosphate
dehydrogenase
CAGAACATCATCCCTGCTTC 187 59 100 0.998
ATGCCTGCTTCACCACCTTC
H2A Histone H2A type 1-C ATATTCAGGCCGTGCTGCT 105 60 100 0.999
TTTGGGTTTCAAAGCGTTTC
HPRT1 Hypoxanthine phosphoribosyl-
transferase 1
GGCAAAACAATGCAAACCTT 163 57 100 0.994
CAAGGGCATATCCTACGACAA
SDHA Succinate dehydrogenase
complex, subunit A
TCCATCGCATAAGAGCAAAG 159 59 99 0.997
GGTGGAACTGAACGAACTCC
RPL32 Ribosomal protein L32 AGCCATCTACTCGGCGTCA 149 60 100 0.995
TCCAATGCCTCTGGGTTTC
UBC Ubiquitin C GCAAGACCATCACCCTGGA 206 60 97 0.996
CTAACAGCCACCCCTGAGAC
TUBA4A Tubulin, alpha 4a GCCCTACAACTCCATCCTGA 78 60 100 0.999
ATGGCTTCATTGTCCACCA
Test genes CD40 Cluster of differentiation 40 CAGGAAAGAAACTGGTGAATG 180 62 106 0.993
AAGTGGCGTCTGTTGTTGAG
CD80 Cluster of differentiation 80 CACCTTCACCGACATCACC 106 62-64 102 0.995
AGACCCCCTTTCGCTCTTC
CD86 Cluster of differentiation 86 AGTATAAAGGCCGCACAAGC
CCTTGGGTAGATGAGCAGGT
247 63 95 0.990
HGF Hepatocyte growth factor TGCATTCAAGGTCAAGGAGA
TTTTGGAATTTGGGAGCAGT
234 63 84 0.983
IDO Indoleamine 2,3-dioxygenase ACAACATCAGGACCAGGACAC
TCCAGACGCCTTCATAGAG
198 61-64 72 0.957
TGFβ Transforming growth factor-β GGAATGGCTGTCCTTTGATG
CGGAGTGTGTTATCTTTGCTGTC
120 61-64 92 0.997
TNFα Tumor necrosis factor-α GCCTCAGCCTCTTCTCCTTC
GGCTTGTCACTTGGGGTTC
172 62-64 113 0.999
Ta, annealing temperature.
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the most stable genes in MSC samples, since the average
expression stability values (or M values) of these genes
ranged between 0.35 and 0.4, indicating a very good sta-
bility (Figure 1A). The pairwise variation calculation
showed that at least four reference genes should be used
for normalization (Figure 1B).
Primers for the immunomodulatory (co)factors CD40,
CD80, CD86, HGF, IDO, TGFβ, and TNFα were designed
by means of Primer3 software [25], based on horse se-
quences found in the National Center for Biotechnology
Information (NCBI) GenBank [26] (Table 2). Primers
were, where possible, selected over intron-exon boundar-
ies, tested by using a Basic Local Alignment Search Tool
(BLAST) analysis against the NCBI database and tested
for secondary structure formation by using MFold [27].
The optimal quantitative PCR (qPCR) conditions weredetermined on cDNA of mixed equine tissues consisting
of PB, MSCs, and endothelial cells.
qPCR analyses were performed in accordance with
the MIQE (Minimum Information for Publication of
Quantitative Real-Time PCR Experiments) guidelines
[28] on the CFX96 Touch Real-Time PCR Detection
System (Bio-Rad) by using the SsoAdvanced SYBR green
supermix (Bio-Rad) and 0.2 mL thin-walled 96-well PCR
plates (Bio-Rad). Each 10 μL qPCR reaction consisted of
5 μL of SsoAdvanced SYBR green master mix, 200 nM of
each specific primer, and 2 μL of 10× diluted cDNA. The
PCR program started with an initial 3-minute denatur-
ation at 95°C to activate the DNA polymerase, followed
by 45 cycles of denaturation at 95°C for 20 seconds and
a combined primer annealing/extension at the specific
annealing temperature for 40 seconds during which
fluorescence was measured. The level of mRNA
Figure 1 Determination of the stability and number of reference genes. (A) Average expression stability values of eight commonly used
reference genes. (B) Determination of the optimal number of reference genes to be used for normalization. The Y-axis represents the pairwise
variation value V between the normalization factors NFn and NFn + 1. Pairwise variation values are calculated for every series of NFn and NFn + 1
normalization factors, reflecting the effect of adding an (n + 1)th gene.
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melt curve analysis followed by agarose gel electrophor-
esis was performed to test for primer-dimer formation
and specificity of the amplicons. Each qPCR was exe-
cuted in duplicate, no template and no RT controls were
included (Cq > 45), and a 6-point, fivefold serial dilution
series made of cDNA isolated from equine blood,
MSCs, and endothelial cells gave information about the
PCR efficiencies, the correlation coefficients (Table 2),
the slopes, and the Y-intercepts of the assays. Cq values
were converted into raw data and analyzed by the ΔΔCq
method as described by Hellemans and colleagues [29]
and normalized by using the geometric mean of the four
most stably expressed reference genes.Statistical analysis
Data were presented as mean ± standard deviation. Linear
regression models were fit to determine the association
between the source of MSCs (UCB, UCM, PB) and (i) the
moment of first observation, (ii) the moment of first
passage, (iii) cell proliferation data (that is, CDN and
PDT), (iv) the expression of markers related to cell im-
munogenicity (that is, MHC-I and MHC-II), and (v) the
mRNA profile of all immunomodulatory factors, except
for HGF as no normal distribution could be obtained
for the latter variable. To evaluate the association be-
tween the source of MSCs and the mRNA expression of
HGF, the non-parametric Kruskal-Wallis test was per-
formed instead. To minimalize inter-horse variability,
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within the same mare and for UCB and UCM even
within the same foal from that specific mare. In all lin-
ear regression models, mare was forced into the model
to exclude mare-specific effects. Normality was checked
by the Kolmogorov-Smirnov test. To approximate nor-
mality, a reciprocal (CD105) or arcsin-transformation
(CD44, CD90, subset 2, CD79, MHC-1, monocyte marker,
subset 4) of the different markers was performed. A recip-
rocal transformation was also used to obtain a normal dis-
tribution of the PDT. In all models, statistical significance
was assessed at P<0.05. The fit of the linear regression
models was evaluated by examination of the normal prob-
ability plots of residuals and by inspection of the residuals
plotted against the predicted values. Least square means
were calculated. All analyses were performed by using
SPSS 19.0 (SPSS, Inc., Chicago, IL, USA).
Results
Success rate of isolating equine mesenchymal
stromal cells
UCB, UCM, and PB samples were collected from six mares
with a normal parturition, and putative equine MSCs could
be isolated from all three sources (Table 3). All adherent
cell populations had the typical spindle-shaped fibroblast-
like cells morphology, irrespectively of the source used. An
isolation success rate of 100% was found for MSC isolation
from both UCB and PB. For the isolation of MSCs from
UCM, however, MSCs could be obtained from two out of
the six samples because of bacterial contamination issues
(Table 3).
Interestingly, adherent cells could be observed in the
UCB samples on average as early as 8 days after culturing,
in contrast to UCM and PB samples, in which adherent
cells were first spotted around 14 days (P<0.01) (Table 3).
Cell proliferation
Kinetic parameters such as the CDN and PDT enable a
good monitoring of a culture during serial passage by cal-
culating cell yields (CDN) and growth rates (PDT). To as-
sess cell proliferation, CDN and PDT were determined for
MSCs from all three sources between passages 2 and 5,
and the overall results indicated that MSCs were able to
rapidly divide in vitro, irrespectively of their source. WithTable 3 Descriptive statistics of the success rate ± standard de
the effect of MSC source on the moment of first observation
the isolation of putative equine MSCs from 6 UCB, PB, and U
Source Success rate, percentage
UCB 100
PB 100
UCM 33.3
aUmbilical cord blood (UCB) significantly different from peripheral blood (PB) and uregard to the CDN data, no statistically significant differ-
ences were observed between sources (Figure 2A). In
addition, PDT values did not substantially differ between
the different sources with the exception of passage 3, in
which the PDT of UCB-derived MSCs (1.24 ± 0.28 days)
was significantly lower than the PDT of PB- and UCM-
derived MSCs (1.75 ± 0.61 days and 1.64 ± 0.69 days, re-
spectively) (Figure 2B) (P<0.05). This was shown to be pri-
marily due to the source-specific cell division patterns
(Table 4). The PDT of UCB increased from 1.20 ± 0.26 at
passage 2 to 2.23 ± 1.31 at passage 5, while the PDT of PB
and UCM, respectively, steeply increased from 1.24 ± 0.27
and 1.10 ± 0.25 at passage 2 to 1.75 ± 0.61 and 1.64 ± 0.69
at passage 3 and then subsequently decreased to 1.71 ±
0.58 and 1.08 ± 0.24 at passage 4 and to 1.29 ± 0.31 and
1.13 ± 0.27 at passage 5, respectively (Figure 2B). In
conclusion, the PDT for UCB-derived MSCs gradually
increased while the PDT for PB- and UCM-derived
MSCs was initially higher in comparison with UCB-
derived MSCs but then substantially decreased.
Tri-lineage differentiation potential
Osteogenic differentiation was confirmed in all six UCB
and PB samples by an increased expression of alkaline
phosphatase activity as well as an Alizarin Red S-positive
histological staining (Figure 3), with the exception of
the set of UCB/PB samples from one mare, in which no
calcium deposits could be detected with Alizarin red S
(data not shown). In MSCs isolated from the two non-
contaminated UCM samples, an increased alkaline phos-
phatase activity could be clearly demonstrated but these
samples were negative for the Alizarin Red S staining
(Figure 3). No difference in chondrogenic and adipogenic
differentiation potential was noticed for MSCs derived
from either source, and all MSCs readily differentiated to-
ward chondrocytes, as evaluated by a positive Alcian blue
staining, and toward adipocytes, as evaluated by a positive
Oil Red O staining (Figure 4).
Immunophenotypical protein profile
An overview of the results obtained for the expression of
the different markers on equine MSCs derived from either
source is given in Table 5. Briefly, although significant var-
iations were observed in the percentage of some markersviation (SD, %) and linear regression model describing
± SD (days) and moment of first passage ± SD (days) of
CM respectively
First observation, days First passage, days
8.5 ± 1.9a 15.8 ± 2.4a
14.5 ± 1.9 19.7 ± 2.4
14.5 ± 2.2 21.5 ± 4.8
mbilical cord matrix (UCM) at P<0.01.
Figure 2 Proliferation data of MSCs derived from UCB, PB, and UCM for passages 2 to 5, expressed by the least square means ± SD of
the CDN (A) and the back-transformed least square means of the PDT (B). Different superscripts (a,b) denote statistically significant
differences between either sources or passages not sharing the same superscript.
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with a high expression of markers known to be expressed
on MSCs and a negligible expression of markers known
to be absent in MSCs (Table 5). However, since both
the absolute difference between the three sources and
the variation within each source were very small, the
biological relevance of these statistically significant dif-
ferences could be questioned. Indeed, such differences
in marker expression might just represent the bio-
logical diversity among the animals, as suggested previ-
ously by Pascucci and colleagues [30]. In addition, the
variable expression of CD105 observed in the present
study is consistent with our previous studies and has
been extensively discussed [18,21,31].
When evaluating vitality, using 7-AAD as a cell viability
stain, a consistently higher amount of dead cells was
observed in PB-derived MSC cultures (13.3% ± 1.3%)
compared with UCB-derived (7.7% ± 1.3%) or UCM-
derived (5.4% ± 0.8%) MSCs (P<0.001).Immunomodulatory mRNA profile
Finally, we also wanted to study and compare the ex-
pression of several immunomodulatory factors, which
are well studied in human MSC immunobiology [4], in
our equine MSCs obtained from the three sources. To
this end, mRNA expression of the different factors was
evaluated by reverse transcription-quantitative PCR
(RT-qPCR). Equine MSCs showed a moderate to strong
expression of the co-stimulatory molecules CD40 and
CD80, irrespectively of the source, with a significantly
lower expression for CD80 on UCB-derived MSCs com-
pared with PB-derived MSCs (P<0.05) (Figure 5). In
contrast, no CD86 expression was found in MSCs from
all three sources (Figure 5).
Additionally, the equine MSCs were examined for the
expression of genes encoding several cytokines and growth
factors such as HGF, IDO, TGFβ, and TNFα. A strong ex-
pression was observed for TGFβ, followed by a moderate
to weak expression of HGF, again irrespectively of source
Table 4 Linear regression model describing the effect of
the source of equine MSC and the passage on the
reciprocal transformed PDT
Independent variable na Estimateb SEc LSMd P value
Mare 6 … … … <0.001
Source 0.12
Umbilical cord blood 6 ref. … 1.49 …
Peripheral blood 6 0.02 0.05 1.47 0.75
Umbilical cord matrix 2 0.16 0.08 1.21 0.04
Passage 0.03
2 14 ref. … 1.18 …
3 12 −0.18 0.07 1.51 0.01
4 11 −0.15 0.07 1.42 0.03
5 10 −0.14 0.07 1.42 0.04
Source x passagee … … … … <0.001
aNumber of observations. bReciprocal transformation of population doubling
time. cStandard error of the mean. dBack-transformed least square means.
eEstimates are not shown. See Figure 2 for least square mean values for
different comparisons.
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and TNFα in all samples tested (Figure 5).
Discussion
In this study, we aimed to thoroughly evaluate and com-
pare three minimally invasive sources to obtain equine
MSCs (that is, UCB, UCM, and PB) in order to define the
most valuable source for regenerative purposes. This in-
cluded assessment of success rate of isolation, proliferation
potential, and differentiation capacities and evaluation
of their immunophenotypical and immunomodulatory
profiles. The latter profile may be important in view ofFigure 3 Osteogenic differentiation potential. Representative example o
and umbilical cord matrix- (UCM-) derived mesenchymal stromal cells (MSC
demonstrated by an increased alkaline phosphatase activity and the Alizari
alkaline phosphatase activity but negative for Alizarin Red S. Magnificationenvisaged allogeneic future applications. To minimalize
animal-dependent influences between the different sources,
the samples of the three tissue sources were at least
matched within the same mare and for UCB and UCM
even within the same foal from that specific mare. As
such, we significantly reduced the large variability in age
and breed of the horses [32]. As an overall conclusion, we
propose UCB as the most valuable, non-invasive source
for equine MSCs on the basis of the following observa-
tions. Firstly, an isolation success rate of 100% was found
for MSC isolation from both UCB and PB, which might
indicate that the isolation methods and culture conditions
for equine MSCs from these sources have been optimized.
Since obtaining contamination-free UCM cultures was
found to be problematic and fungal or bacterial contamin-
ation has also been described in other studies using UCM
as a source for MSCs [33-35], we concluded that this tis-
sue is a less appealing source for equine MSCs. Secondly,
MSCs were first observed in the UCB samples and this
could not be explained by the number of peripheral blood
mononuclear cells (PBMCs) originally seeded, since this
was kept constant for all blood samples tested. It might,
however, be explained by the fact that the concentration
of circulating MSCs in PB is likely very low [13,32,36,37].
As the explants of the UCM were immediately transferred
to culture flasks and MSCs were supposed to migrate
from these explants, it is not known how many UCM-
derived cells were initially seeded. However, one might
suppose that the cells from the UCM need extra time to
migrate out of the explants instead of just adhering to the
culture flask, which might explain why MSCs were ob-
served in a later stage when compared with UCB. Thirdly,
regarding the osteogenic differentiation, UCM-derivedf isolated equine umbilical cord blood- (UCB-), peripheral blood- (PB-),
s) which were able to differentiate toward the osteogenic lineage, as
n Red S staining. MSCs derived from UCM are staining positive for
10×.
Figure 4 Chondrogenic and adipogenic differentiation potential. A representative example of isolated equine mesenchymal stromal cells
(MSCs) derived from umbilical cord blood (UCB), peripheral blood (PB), and umbilical cord matrix (UCM) was shown to demonstrate the
chondrogenic and adipogenic differentiation. Magnification 40× (chondrogenic differentiation) and 20× (adipogenic differentiation).
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ical feature of the more mature stage of osteogenesis, and
thus did not differentiate toward fully matured osteocytes.
Increasing the serum concentration in the osteogenic
differentiation medium from 10% to 20% might have en-
hanced the osteogenic potential of our UCM-derived
MSCs, as previously described by Toupadakis and col-
leagues [11], but this was not evaluated in our present
study, because we wanted to keep the osteogenic medium
identical for all three MSC sources tested.
Allogeneic applications for regenerative therapies are
an attractive approach since allogeneic MSCs would
provide an off-the-shelf, more standardized, and readilyTable 5 Immunophenotypical characterization of equine
mesenchymal stromal cells derived from umbilical cord
blood, peripheral blood, and umbilical cord matrix,
expressed as the percentage of cells positive for
each marker
Marker UCB PB UCM
CD29pos 99.6 ± 0.2a 98.2 ± 0.9a 98.4 ± 1.0a
CD44pos 99.2 ± 0.2b 96.6 ± 4.1 97.3 ± 1.1
CD73pos 0.5 ± 0.5c,d 0.8 ± 0.5 0.5 ± 0.1
CD90pos 99.4 ± 0.3 97.8 ± 2.4 66.9 ± 27.6a
CD105pos 2.7 ± 3.4 1.2 ± 1.6 46.2 ± 64.3
MHC-Ipos 80.3 ± 12.9 62.7 ± 24.8c 77.6 ± 11.8
CD45neg 0.5 ± 0.3 1.8 ± 0.9 1.1 ± 1.4
CD79αneg 0.1 ± 0.1c 1.0 ± 1.0c 0.1 ± 0*
Monocyte markerneg 0.2 ± 0.1b,d 1.3 ± 1.2 1.0 ± 1.3
MHC-IIneg 0.5 ± 0.5 0.8 ± 0.7 0.8 ± 0.6
Indicated source is significantly different from both other sources at least at
aP<0.001, bP<0.01, cP<0.05. dOnly significantly different from peripheral blood
(PB). Data are presented as average ± standard deviation (n = 6, except for
umbilical cord matrix (UCM), n = 2). UCB, umbilical cord blood.available product without the inherent lag period asso-
ciated with isolation and expansion of autologous MSCs
[7]. A potential drawback of using allogeneic MSCs,
however, might be their immunogeneic properties which
could lead to an immune response in the acceptor host
and, hence, rejection reactions. For equine MSCs, how-
ever, not much information regarding their immunogenic/
immunomodulatory profiles is available. Therefore, we
initiated an evaluation and comparison of important
immunological factors in equine MSCs from the three
sources tested in this study.
First, the expressions at the protein level of the histo-
compatibility markers MHC-I and MHC-II were evaluated
by flow cytometry. Equine MSCs from all sources showed
a moderate to high expression of MHC-I, ranging from
62.7% ± 24.8% for PB to 80.3% ± 12.9% for UCB, while the
expression of MHC-II was lacking in all MSC samples,
which is similar to what has been previously described
[10,38]. In a study by Guest and colleagues [38], a lower
expression of MHC-I on UCB-derived MSCs was found
when compared with BM-derived MSCs. However, the
presence of MHC-I on MSCs seems less important when
evaluating the ability of MSCs to elicit acute graft rejection
or cell-mediated delayed-type hypersensitivity responses
in allogeneic settings, since it was recently demonstrated
by Carrade and colleagues [10] that the intradermal in-
jection of allogeneic MSCs generated only a limited,
self-resolving dermal histopathologic response, similar
to the injection of saline. The same study by Guest and
colleagues [38] found no expression of MHC-II on both
BM-derived and UCB-derived MSCs. After treatment with
IFN-γ, MHC-II expression was induced on BM-derived
MSCs but not on UCB-derived MSCs, suggesting that
MSCs from neonatal sources are less immunogenically
Figure 5 Differential gene expression in UCB-, UCM-, PB-derived MSCs, as determined by RT-qPCR. Mean normalized expression and error
bars with 5% value are displayed. *P<0.05.
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stimulation of equine MSCs was not performed in our
present study, but future experiments are planned to
evaluate whether the absence of MHC-II on these cells
will translate into their inability to stimulate host cells
in vitro as well as in vivo. Hereby, we anticipate that our
equine MSCs will not be immunogenic or will be only
low immunogenic, based on in vitro studies which have
demonstrated that human BM-derived MSCs induced
no proliferative response in mixed lymphocyte reactions,
even after IFN-γ stimulation and induction of MHC-II
expression [39].
Additionally, the expression of the co-stimulatory mole-
cules CD40, CD80, and CD86 was evaluated by using
qPCR as no antibodies for these molecules are available
that cross-react with the equine counterparts, at least to
our knowledge. These molecules are required to trigger
and amplify the response of the T-helper cell responses
once initial T-cell activation is achieved [6,40] and have
been shown to be absent in human MSCs [5,41]. In line
with what has been described for human MSCs, no ex-
pression of CD86 was detected in equine MSCs. However,
we found that our equine MSCs did express CD40 and
CD80, with a significantly lower expression for CD80 on
UCB-derived MSCs compared with PB-derived MSCs.
Differences in expression levels of immunogenic mole-
cules as well as in their release of tolerogenic factors be-
tween umbilical cord lining- and BM-derived MSCs have
been previously reported in humans, which reinforces the
fact that MSCs derived from neonatal sources are pre-
ferred from an immunomodulation point of view based
on their higher proliferative capacity and lower immuno-
genicity when compared with MSCs from an adult source
[5]. Indeed, it has been demonstrated that fetal-derivedhuman MSCs (1) are less immunogenic, (2) cause less im-
mune activation, (3) get rejected more slowly, (4) were
able to suppress lymphocyte proliferation to a significantly
greater extent, and (5) are more immunogenically inert,
when compared with MSCs derived from adult human
sources [5,42-46]. Still, the importance of our findings
must be confirmed by evaluating the expression of these
molecules on a functional level. On the other hand, MHC-
II molecules are essential to initiate the T-cell responses,
and since our equine MSCs lack expression of this mol-
ecule, it can be anticipated that the presence of CD40 and
CD80 might not be that detrimental. Indeed, in a study by
Kluyshnenkova and colleagues [41], it was found that
transduction of human MSCs (which are also MHC-II-
negative) with CD80 failed to elicit a strong proliferative
T-cell response. It has to be noted, however, that im-
portant differences exist between T-cell subpopulations
regarding the requirement for co-stimulatory signals. For
example, memory T cells are relatively independent of
these signals, and, as such, lower levels of co-stimulation
might be sufficient to elicit T-cell responses. Secondly, we
also evaluated the expression of several cytokines with
known immunomodulatory properties, like TFG-β, HGF,
TNF-α, and IDO. TFG-β and HGF, cytokines with im-
munosuppressive properties, were expressed in MSCs
from all three sources. As previously reported, these
cytokines function synergistically to suppress T-cell
proliferation [41,47]. Moreover, it has been suggested
that the basal secretion of TFG-β by equine MSCs may
be sufficient to inhibit the T-cell proliferation which is
seen in vitro after stimulation [3]. As for TNF-α, this is a
pro-inflammatory cytokine which mediates inflammation
[6]. In mixed lymphocyte reactions in which either allo-
geneic MSCs or PBMCs were used to elicit T-cell
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sponse to MSC stimulators when compared with PBMC
stimulators [41]. In the study by Yoo and colleagues [2],
non-stimulated human MSCs from different sources
(that is, BM, adipose tissue, UCB, and UCM) did not se-
crete TNF-α, with the exception of two isolates from UCB
and one isolate from UCM, which is in line with our re-
sults. In humans, it is known that IDO is a cytokine which
is strongly upregulated in stimulated MSCs and results in
the inhibition of T-cell proliferation [2,5]. In the present
study, we did not find IDO expression in any MSC sample,
but it has to be mentioned that we used non-stimulated
MSCs for our qPCR analyses. Still, because it has been
described that equine MSCs in the presence of stimulated
T cells failed to produce IDO [3], the latter cytokine most
likely does not play an important role in defining the
immunosuppressive properties of equine MSCs.
Conclusions
In the present study, a comparative analysis was carried
out with equine UCB-, UCM-, and PB-derived MSCs ori-
ginating from the same horse. Our data strengthen recent
findings that inherent differences exist between MSCs
from different tissues, as suggested for human MSCs [6].
Combining all the observations in this present study, we
propose UCB as the most promising non-invasive alterna-
tive source for MSCs and UCM as the least feasible source
because of high contamination risks. Moreover, our data
indicate that UCB-derived MSCs could be suited for allo-
geneic use, although their immunogenicity potential needs
to be addressed in more detail in future studies.
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